Business Context and Reporting Period
Company: Geron Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2009
Business Overview: Geron is a biopharmaceutical company developing first-in-class therapies for cancer and chronic degenerative diseases. Key programs include telomerase-targeted oncology drugs (GRN163L, GRNVAC1) and human embryonic stem cell (hESC)-based therapies (GRNOPC1 for spinal cord injury). The company has no approved products and relies on licensing, collaboration, and equity financing.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended June 30, 2009 |
6 Months Ended June 30, 2009 |
6 Months Ended June 30, 2008 |
|---|---|---|---|
| Total Revenues | $183 | $627 | $1,892 |
| Research & Development Expenses | $15,112 | $28,883 | $25,227 |
| General & Administrative Expenses | $3,828 | $7,206 | $8,072 |
| Net Loss | $(19,758) | $(36,569) | $(27,238) |
| Net Loss per Share (Basic/Diluted) | $(0.23) | $(0.43) | $(0.35) |
| Cash and Cash Equivalents | $101,371 | $101,371 | $127,080 |
| Marketable Securities | $86,475 | $86,475 | $53,491 |
| Total Liquidity (Cash + Securities) | $187,846 | $187,846 | $180,571 |
| Accumulated Deficit | $(543,652) | $(543,652) | $(506,893) |
Cash Flow (6 Months Ended June 30, 2009):
- Net cash used in operating activities: $(20,547)
- Net cash used in investing activities: $(34,456)
- Net cash provided by financing activities: $47,026 (primarily from a public offering in February 2009)
Material Changes vs. Prior Period
- Revenue Decline: Total revenues dropped significantly from $1.89 million in the first half of 2008 to $0.63 million in the first half of 2009. This was driven by the absence of a $1.5 million milestone payment recognized in 2008 related to a joint venture agreement with Exeter Life Sciences.
- Increased R&D Spend: Research and development expenses increased by approximately 14.5% year-over-year for the six-month period ($28.9M vs $25.2M). Increases were attributed to higher manufacturing costs for GRN163L, GRNVAC1, and GRNOPC1, increased clinical trial costs due to patient enrollment, and higher personnel costs.
- Derivative Losses: The company recorded an unrealized loss on derivatives of $1.25 million for the six months ended June 30, 2009, compared to an unrealized gain of $0.9 million in the prior year period. This reflects changes in the fair value of warrant liabilities.
- Equity Method Losses: The company recognized $0.66 million in losses related to its investment in ViaGen, Inc., a joint venture, which was not present in the comparable 2008 period.
Guidance, Outlook, and Risks
Outlook and Liquidity: Management estimates that existing capital resources, interest income, and an equipment financing facility will be sufficient to fund operations through at least December 2010. The company anticipates continued operating losses as it advances clinical trials for GRN163L, GRNVAC1, and GRNOPC1.
Recent Developments:
- Entered a worldwide exclusive license and alliance agreement with GE Healthcare UK Limited (GEHC) on June 29, 2009, to develop cellular assay products derived from hESCs. No payments had been received as of June 30, 2009.
- Received FDA clearance in January 2009 to begin the first human clinical trial of GRNOPC1 for acute spinal cord injury.
Key Risks and Contingencies:
- Capital Needs: The company has a history of losses and an accumulated deficit of $543.7 million. Future capital requirements are substantial, and there is no assurance that additional funding will be available on favorable terms.
- Regulatory and Clinical Risk: Product candidates are in early stages. Success depends on obtaining regulatory approvals, which is a costly, lengthy, and uncertain process. Clinical trial results may not demonstrate efficacy or safety.
- Intellectual Property: The company faces risks related to patent challenges, including oppositions in Europe regarding hESC technologies and potential reexaminations of U.S. patents.
- Collaboration Dependence: Success relies on third-party collaborators for manufacturing, clinical trials, and commercialization.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $187.8 million liquidity position against the projected burn rate, given the lack of product revenue.
- Derivative Liabilities: Review the valuation assumptions (volatility, interest rates) for the $2.4 million derivative liability, as fluctuations significantly impact net loss.
- GE Healthcare Agreement: Monitor the timing and magnitude of upfront payments and milestone triggers under the new GEHC alliance.
- Clinical Trial Progress: Track enrollment and safety data for the GRN163L, GRNVAC1, and GRNOPC1 trials, as delays or negative results could necessitate immediate capital raises.
- Patent Status: Monitor the outcome of the European Patent Office (EPO) appeals regarding hESC patentability and the U.S. reexamination of WARF patents.